Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma

Melanoma is a deadly disease that often exhibits relentless progression and can have both early and late metastases. Recent advances in immunotherapy and targeted therapy have dramatically increased patient survival for patients with melanoma. Similar advances in molecular targeted PET imaging can identify molecular pathways that promote disease progression and therefore offer physiological information. Thus, they can be used to assess prognosis, tumor heterogeneity, and identify instances of treatment failure. Numerous agents tested preclinically and clinically demonstrate promising results with high tumor-to-background ratios in both primary and metastatic melanoma tumors. Here, we detail the development and testing of multiple molecular targeted PET-imaging agents, including agents for general oncological imaging and those specifically for PET imaging of melanoma. Of the numerous radiopharmaceuticals evaluated for this purpose, several have made it to clinical trials and showed promising results. Ultimately, these agents may become the standard of care for melanoma imaging if they are able to demonstrate micrometastatic disease and thus provide more accurate information for staging. Furthermore, these agents provide a more accurate way to monitor response to therapy. Patients will be able to receive treatment based on tumor uptake characteristics and may be able to be treated earlier for lesions that with traditional imaging would be subclinical, overall leading to improved outcomes for patients.

[1]  A. Lallas,et al.  European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. , 2022, European journal of cancer.

[2]  T. Sarna,et al.  Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship , 2022, Frontiers in Oncology.

[3]  R. Hicks,et al.  PET/CT variants and pitfalls in malignant melanoma , 2022, Cancer Imaging.

[4]  Hubing Wu,et al.  [18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04 , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  U. Reineke,et al.  Abstract LBA032: Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286 , 2021, Poster Presentations - Late-Breaking Proffered Abstracts.

[6]  S. Aerts,et al.  Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value , 2021, Frontiers in Oncology.

[7]  E. Lopci Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer , 2021, Journal of clinical medicine.

[8]  W. Hayes,et al.  Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic , 2021, Frontiers in Oncology.

[9]  D. Jäger,et al.  FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  M. Pomper,et al.  First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients , 2021, The Journal of Nuclear Medicine.

[11]  L. Schwartz,et al.  Don't overlook spleen glucose metabolism on [18F]-FDG PET/CT for cancer drug discovery and development. , 2021, Current cancer drug targets.

[12]  E. Moscarella,et al.  Usefulness of High-Frequency Ultrasonography in the Diagnosis of Melanoma: Mini Review , 2021, Frontiers in Oncology.

[13]  Hsin-Ell Wang,et al.  Development of Radiofluorinated Nicotinamide/Picolinamide Derivatives as Diagnostic Probes for the Detection of Melanoma , 2021, International journal of molecular sciences.

[14]  Xue-juan Wang,et al.  Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPI PET/CT , 2021, The Journal of Nuclear Medicine.

[15]  L. Vercellino,et al.  Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy , 2021, Frontiers in Oncology.

[16]  M. Egger The Role of Clinical Prediction Tools to Risk Stratify Patients with Melanoma After a Positive Sentinel Lymph Node Biopsy , 2021, Annals of Surgical Oncology.

[17]  J. Nosanchuk,et al.  Fungal Melanin and the Mammalian Immune System , 2021, Journal of fungi.

[18]  M. Pomper,et al.  Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules. , 2021, Journal of medicinal chemistry.

[19]  Dale Han,et al.  Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma , 2021, Current Treatment Options in Oncology.

[20]  Xiangxi Meng,et al.  Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab , 2021, Clinical nuclear medicine.

[21]  N. Aide,et al.  Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  L. Qiu,et al.  Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers , 2021, Cancer Immunology, Immunotherapy.

[23]  F. Facchiano,et al.  Nicotinamide inhibits melanoma in vitro and in vivo , 2020, Journal of experimental & clinical cancer research : CR.

[24]  M. Moncrieff,et al.  Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management , 2020, Annals of Surgical Oncology.

[25]  Hsin-Ell Wang,et al.  Evaluation of Radioiodinated Fluoronicotinamide/Fluoropicolinamide-Benzamide Derivatives as Theranostic Agents for Melanoma , 2020, International journal of molecular sciences.

[26]  Jinming Yu,et al.  18F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancer , 2020, Translational lung cancer research.

[27]  Evan P. Stater,et al.  Synthesis of the PET Tracer 124I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring , 2020, The Journal of Nuclear Medicine.

[28]  Hyung-Seok Kim,et al.  Ultrasensitive detection of malignant melanoma using PET molecular imaging probes , 2020, Proceedings of the National Academy of Sciences.

[29]  S. de Jong,et al.  Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer 18F-BMS-986192 , 2020, The Journal of Nuclear Medicine.

[30]  L. Schwartz,et al.  Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4 , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  G. Argenziano,et al.  A preliminary study for quantitative assessment with HFUS (High Frequency ultrasound) of nodular skin melanoma Breslow thickness in adults before surgery: Interdisciplinary team experience. , 2020, Current radiopharmaceuticals.

[32]  J. Klubo-Gwiezdzinska,et al.  Targeting Integrins with Radiolabeled RGD Analogs for Radiotheranostics of Metastatic Radioactive Iodine Non-Responsive Thyroid Cancer - New Avenues in Personalized Medicine. , 2020, Thyroid : official journal of the American Thyroid Association.

[33]  C. H. Nielsen,et al.  Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  G. Calais,et al.  Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France. , 2019, European journal of cancer.

[35]  L. Vercellino,et al.  Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab , 2019, The Journal of Nuclear Medicine.

[36]  C. Lebbé,et al.  Severe Gastrointestinal Toxicity of MEK Inhibitors. , 2019, Melanoma research.

[37]  E. Jones,et al.  68Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. , 2019, Radiology. Imaging cancer.

[38]  L. Schwartz,et al.  Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  Xiaoling Hu,et al.  89Zr-Labeled Anti-PD-L1 Antibody Fragment for Evaluating In Vivo PD-L1 Levels in Melanoma Mouse Model. , 2019, Cancer biotherapy & radiopharmaceuticals.

[40]  S. Swetter,et al.  Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[41]  R. Turner,et al.  False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma , 2019, Annals of Surgical Oncology.

[42]  R. Houot,et al.  Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[43]  R. Boellaard,et al.  Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer , 2018, Nature Communications.

[44]  Ronald Boellaard,et al.  89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer , 2018, Nature Medicine.

[45]  Thomas Lindner,et al.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.

[46]  C. Balleyguier,et al.  Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. , 2018, European journal of cancer.

[47]  Xiaohu Zhao,et al.  Biodistribution, Radiation Dosimetry, and Clinical Application of a Melanin-Targeted PET Probe, 18F-P3BZA, in Patients , 2018, The Journal of Nuclear Medicine.

[48]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[49]  J. Talbot,et al.  Comparison and evaluation of two RGD peptides labelled with 68Ga or 18F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma , 2018, Oncotarget.

[50]  A. Casadevall,et al.  Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy , 2018, Scientific Reports.

[51]  A. Mackiewicz,et al.  BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients , 2018, Contemporary oncology.

[52]  R. Houot,et al.  Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. , 2018, European journal of cancer.

[53]  Lawrence H. Schwartz,et al.  (18)F-FDG PET and CT-scan Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-PD1 Immune Checkpoint Inhibitor , 2018 .

[54]  C. Craik,et al.  Imaging PD-L1 Expression with ImmunoPET , 2017, Bioconjugate chemistry.

[55]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[56]  L. Mansi,et al.  Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  J. Utikal,et al.  Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. , 2017, European journal of cancer.

[58]  Yingying Zhang,et al.  Detection of melanoma metastases with PET-Comparison of 18F-5-FPN with 18F-FDG. , 2017, Nuclear medicine and biology.

[59]  P. Garg,et al.  4-11C-Methoxy N-(2-Diethylaminoethyl) Benzamide: A Novel Probe to Selectively Target Melanoma , 2017, The Journal of Nuclear Medicine.

[60]  D. Rigel,et al.  Analysis of Trends in US Melanoma Incidence and Mortality , 2017, JAMA dermatology.

[61]  N. Moins,et al.  Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy1 , 2016, Neoplasia.

[62]  P. Merlet,et al.  [18F]MEL050 as a melanin-targeted PET tracer: Fully automated radiosynthesis and comparison to 18F-FDG for the detection of pigmented melanoma in mice primary subcutaneous tumors and pulmonary metastases. , 2016, Nuclear medicine and biology.

[63]  D. Colin,et al.  Preclinical validations of [18F]FPyPEGCBT-c(RGDfK): a 18F-labelled RGD peptide prepared by ligation of 2-cyanobenzothiazole and 1,2-aminothiol to image angiogenesis , 2016, EJNMMI Radiopharmacy and Chemistry.

[64]  Hsin-Ell Wang,et al.  Preparation and characterization of a novel Al(18)F-NOTA-BZA conjugate for melanin-targeted imaging of malignant melanoma. , 2016, Bioorganic & medicinal chemistry letters.

[65]  Wojciech G. Lesniak,et al.  PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. , 2016, Bioconjugate chemistry.

[66]  M. Askarian-Amiri,et al.  Signaling Pathways in Melanogenesis , 2016, International journal of molecular sciences.

[67]  Z. Rzepka,et al.  From tyrosine to melanin: Signaling pathways and factors regulating melanogenesis. , 2016, Postepy higieny i medycyny doswiadczalnej.

[68]  A. Brożyna,et al.  Melanin content in melanoma metastases affects the outcome of radiotherapy , 2016, Oncotarget.

[69]  A. Ribas,et al.  Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy , 2016, Therapeutic advances in medical oncology.

[70]  P. Rutkowski,et al.  Trametinib: a MEK inhibitor for management of metastatic melanoma , 2015, OncoTargets and therapy.

[71]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[72]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[73]  Hsin-Ell Wang,et al.  Synthesis and evaluation of ¹²³/¹³¹I-Iochlonicotinamide as a novel SPECT probe for malignant melanoma. , 2015, Bioorganic & medicinal chemistry.

[74]  D. Colin,et al.  A novel 2-cyanobenzothiazole-based (18)F prosthetic group for conjugation to 1,2-aminothiol-bearing targeting vectors. , 2015, Organic & biomolecular chemistry.

[75]  K. Pitman,et al.  [99mTc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial , 2015, Annals of Surgical Oncology.

[76]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  O. Prante,et al.  PET Radiopharmaceuticals for Imaging Integrin Expression: Tracers in Clinical Studies and Recent Developments , 2014, BioMed research international.

[78]  A. Lambeir,et al.  Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). , 2014, Journal of medicinal chemistry.

[79]  R. Elashoff,et al.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma. , 2014, The New England journal of medicine.

[80]  A. Brożyna,et al.  Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. , 2013, Human pathology.

[81]  F. Penault-Llorca,et al.  In vivo efficacy of melanoma internal radionuclide therapy with a 131I‐labelled melanin‐targeting heteroarylcarboxamide molecule , 2013, International journal of cancer.

[82]  S. O'toole,et al.  BRAF inhibitor activity in V600R metastatic melanoma. , 2013, European journal of cancer.

[83]  A. Casadevall,et al.  Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma , 2013, Journal of skin cancer.

[84]  S. Gottschalk,et al.  Cancer-associated fibroblasts as targets for immunotherapy. , 2012, Immunotherapy.

[85]  A. Hauschild,et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  K. Flaherty,et al.  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[87]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[88]  N. Moins,et al.  Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [18F]ICF01006, a highly promising melanoma PET tracer , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[89]  W. Su,et al.  Quantification of Kryptofix 2.2.2 in [18F]fluorine-labelled radiopharmaceuticals by rapid-resolution liquid chromatography , 2012, Nuclear medicine communications.

[90]  D. Cheresh,et al.  αV integrins in angiogenesis and cancer. , 2011, Cold Spring Harbor perspectives in medicine.

[91]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[92]  R. Hicks,et al.  Improved Detection of Regional Melanoma Metastasis Using 18F-6-Fluoro-N-[2-(Diethylamino)Ethyl] Pyridine-3-Carboxamide, a Melanin-Specific PET Probe, by Perilesional Administration , 2011, The Journal of Nuclear Medicine.

[93]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[94]  T. Poli,et al.  Sentinel Node Biopsy in Head and Neck Squamous Cell Cancer: 5-Year Follow-Up of a European Multicenter Trial , 2010, Annals of Surgical Oncology.

[95]  W. Mcbride,et al.  Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. , 2010, Bioconjugate chemistry.

[96]  J. Fernandez-Miranda,et al.  European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. , 2010, Rhinology. Supplement.

[97]  F. Saab,et al.  Comparison of the efficiencies of two TR-FRET methods to detect in vitro natural and synthesized inhibitors of the Raf/MEK/ERK signaling pathway , 2010 .

[98]  M. Pomper,et al.  Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma. , 2010, Cancer research.

[99]  R. Hicks,et al.  High-Contrast PET of Melanoma Using 18F-MEL050, a Selective Probe for Melanin with Predominantly Renal Clearance , 2010, Journal of Nuclear Medicine.

[100]  J. Aguirre-Ghiso,et al.  Dormancy of metastatic melanoma , 2010, Pigment cell & melanoma research.

[101]  S. Gambhir,et al.  Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[102]  R. Hicks,et al.  Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. , 2009, Journal of medicinal chemistry.

[103]  A. Hauschild,et al.  Staging of cutaneous melanoma , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  W. Mcbride,et al.  A Novel Method of 18F Radiolabeling for PET , 2009, Journal of Nuclear Medicine.

[105]  P. Garg,et al.  Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors. , 2009, Bioconjugate chemistry.

[106]  I. Greguric,et al.  Synthesis and evaluation of novel radioiodinated nicotinamides for malignant melanoma. , 2008, Nuclear medicine and biology.

[107]  Fan Wang,et al.  Integrin αvβ3‐targeted cancer therapy , 2008 .

[108]  I. Greguric,et al.  Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. , 2007, Journal of medicinal chemistry.

[109]  Horst Kessler,et al.  Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man , 2006, Clinical Cancer Research.

[110]  M. Schwaiger,et al.  PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[111]  A. Casadevall,et al.  Melanin as a potential target for radionuclide therapy of metastatic melanoma. , 2005, Future oncology.

[112]  Renato Marchesini,et al.  Automated melanoma detection with a novel multispectral imaging system: results of a prospective study , 2005, Physics in medicine and biology.

[113]  M. Gonen,et al.  Characterization of Micrometastatic Disease in Melanoma Sentinel Lymph Nodes by Enhanced Pathology: Recommendations for Standardizing Pathologic Analysis , 2005, The American journal of surgical pathology.

[114]  Horst Kessler,et al.  Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.

[115]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[116]  J. Kirkwood,et al.  Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.

[117]  M. A. Huber,et al.  Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. , 2003, The Journal of investigative dermatology.

[118]  A. Veyre,et al.  123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[119]  W. Lehmann,et al.  Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. , 2000, Journal of medicinal chemistry.

[120]  G. Prota Melanins, melanogenesis and melanocytes: looking at their functional significance from the chemist's viewpoint. , 2000, Pigment cell research.

[121]  J. Lange,et al.  Amelanotic melanoma: the great masquerader. , 2000, Journal of the American Academy of Dermatology.

[122]  J. Park,et al.  Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts* , 1999, The Journal of Biological Chemistry.

[123]  D. Elder,et al.  Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. , 1998, The American journal of pathology.

[124]  W. Holder,et al.  Effectiveness of positron emission tomography for the detection of melanoma metastases. , 1998, Annals of surgery.

[125]  K. Dutschka,et al.  Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[126]  D. Morton,et al.  Prognostic factors in 1,521 melanoma patients with distant metastases. , 1995, Journal of the American College of Surgeons.

[127]  K. Guan,et al.  Dephosphorylation and inactivation of the mitogen-activated protein kinase by a mitogen-induced Thr/Tyr protein phosphatase. , 1993, The Journal of biological chemistry.

[128]  A. Veyre,et al.  Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[129]  J. Boire,et al.  Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[130]  Erkki Ruoslahti,et al.  Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule , 1984, Nature.

[131]  K. Jimbow,et al.  Characterization of melanogenesis and morphogenesis of melanosomes by physicochemical properties of melanin and melanosomes in malignant melanoma. , 1984, Cancer research.

[132]  M. Goldgeier,et al.  The distribution of melanocytes in the leptomeninges of the human brain. , 1984, The Journal of investigative dermatology.

[133]  Gams Ra,et al.  Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). , 1974 .

[134]  R. Lenhard,et al.  Therapy of malignant melanoma with an imidazole carboxamide and bis‐chloroethyl nitrosourea , 1972, Cancer.

[135]  J. Wolter,et al.  Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma , 1971, Clinical pharmacology and therapeutics.

[136]  Luce Jk,et al.  Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). , 1970 .

[137]  Zhen Cheng,et al.  PET Imaging of Melanoma Using Melanin-Targeted Probe. , 2021, Methods in molecular biology.

[138]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[139]  Yongxue Zhang,et al.  Imaging malignant melanoma with 18F-5-FPN , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[140]  W. Ellis,et al.  A Phase 2 study of 99mTc-trofolastat (MIP-1404) to identify prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection: an interim analysis , 2014 .

[141]  W. Mcbride,et al.  A Novel Method of 18 F Radiolabeling for PET , 2009 .

[142]  Xiaoyuan Chen,et al.  Integrin alpha(v)beta(3)-Targeted Cancer Therapy. , 2008, Drug development research.

[143]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[144]  M. Schwaiger,et al.  [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. , 2004, Bioconjugate chemistry.

[145]  A. Veyre,et al.  [Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma]. , 2004, Journal francais d'ophtalmologie.

[146]  M. Schwaiger,et al.  Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. , 2001, Cancer research.

[147]  J C Briggs,et al.  Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.

[148]  J. Bernheim,et al.  [Chemotherapy of melanoma]. , 1974, Acta chirurgica Belgica.

[149]  W. G. Thurman,et al.  Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). , 1970, Cancer chemotherapy reports.